GlassScriptPhysician profile
Doris S Little
NPI 1548320757
$1,767.88
in general payments reported to CMS, 2019-2025
12 companies · $662 in 2025
The $662 reported for 2025 was more than what 78% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $252 · 2023: $281 · 2024: $573 · 2025: $662.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,516.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,515.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $285.86 | 2022-2025 | Yeztugo |
| Abbvie INC. | $282.90 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $203.30 | 2022-2025 | Xifaxan |
| Neurocrine Biosciences, INC. | $194.02 | 2023-2024 | Ingrezza |
| Novo Nordisk INC | $185.43 | 2022-2023 | Wegovy |
| Ani Pharmaceuticals, INC. | $112.58 | 2025 | Purified Cortrophin Gel |
| Eisai INC. | $109.22 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $99.36 | 2024 | Austedo Xr |
| Amgen INC. | $99.06 | 2025 | Evenity |
| Sumitomo Pharma America, INC. | $87.32 | 2023 | Gemtesa |
| Paratek Pharmaceuticals, INC. | $74.13 | 2024 | Nuzyra |
| Acadia Pharmaceuticals INC | $34.70 | 2023 | Nuplazid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Doris Little listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.